Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Tafinlar and Mekinist | dabrafenib and trametinib | Pediatric glioma with a BRAF V600E | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Istodax | Romidepsin | Peripheral T-Cell Lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Folotyn | Pralatrexate | Peripheral T-Cell Lymphoma (PTCL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Adcetris | Brentuximab Vedotin | peripheral T-cell lymphoma (PTCL) | Reimburse | Complete | ||
| Kuvan | Sapropterin dihydrochloride | Phenylketonuria | N/A | Complete | ||
| Palynziq | pegvaliase | Phenylketonuria | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kuvan | Sapropterin dihydrochloride | Phenylketonuria (PKU) | Do not list | Complete | ||
| Kuvan | Sapropterin dihydrochloride | Phenylketonuria (PKU) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Blincyto | Blinatumomab | Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Scemblix | asciminib | Philadelphia chromosome-positive chronic myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 28, 2024